Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection

Daniel González-Requena, Marina Núñez, Inmaculada Jiménez-Nacher, Juan González-Lahoz, Vincent Soriano

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Liver toxicity is a common side effect of antiretroviral therapy, particularly in subjects coinfected with the hepatitis C virus (HCV). The incidence of severe liver toxicity after initiation of treatment with lopinavir (LPV) as well as its possible association with LPV plasma levels were assessed in 120 HIV-infected patients (52% coinfected by HCV). The incidence of severe liver toxicity at 3 months was 1.7% and the cumulative incidence at 12 months was 4%. The development of severe liver toxicity was associated with HCV coinfection but not with LPV plasma levels.

Original languageEnglish (US)
Pages (from-to)698-700
Number of pages3
JournalAIDS Research and Human Retroviruses
Volume20
Issue number7
DOIs
StatePublished - Jul 2004

ASJC Scopus subject areas

  • Immunology
  • Infectious Diseases
  • Virology

Fingerprint

Dive into the research topics of 'Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection'. Together they form a unique fingerprint.

Cite this